Outcome of Henoch-Schönlein purpura 8 years after treatment with a placebo or prednisone at disease onset.

Background: Corticosteroids have been shown not to prevent the development of Henoch-Schönlein nephritis. However, long-term follow-up data are scarce.

Methods: The long-term outcome of patients in a randomized placebo-controlled prednisone study was evaluated 8 years later with a health questionnaire completed by 160/171 (94%) patients and by urine and blood pressure screening (138/171, 81%).

Cyclosporine A vs. methylprednisolone for Henoch-Schönlein nephritis: a randomized trial.

Knowledge about how to treat severe Henoch-Schönlein nephritis (HSN) is scarce. The aim of our study is to compare cyclosporine A (CyA) and methylprednisolone pulses (MP) in the treatment of severe HSN. Out of 24 pediatric HSN patients with nephrotic-range proteinuria or crescentic HSN in kidney biopsy, seven were randomized to receive CyA for 12 months at an initial dose of 5 mg/kg and eight to receive 3 MP pulses of 30 mg/kg followed by prednisone for 4 months.

Renal manifestations of Henoch-Schonlein purpura in a 6-month prospective study of 223 children.

Objective: To assess the risk factors for developing Henoch-Schönlein purpura nephritis (HSN) and to determine the time period when renal involvement is unlikely after the initial disease onset.

Design: A prospective study of 223 paediatric patients to examine renal manifestations of Henoch-Schönlein purpura (HSP). The patient's condition was monitored with five outpatient visits to the research centre and urine dipstick testing at home.

Clinical course of extrarenal symptoms in Henoch-Schonlein purpura: a 6-month prospective study.

Objective: To describe the extrarenal symptoms and clinical course of Henoch-Schönlein purpura (HSP).

Design: A prospective national multicentre trial with 6-month follow-up. Patients A total of 223 newly diagnosed paediatric HSP patients.